We present an interesting case of port site metastasis is a menopausal women subsequent to diagnostic laparoscopy undertaken for chronic pelvic pain, which later proved early ovarian malignancy as the source of primary. While cases of port site metastasis have mostly occurred after extensive disease the possbility of such complication should be in mind at laparoscopy of early cancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Gold nanocomposites in colorectal cancer therapy: characterization, selective cytotoxicity, and migration inhibition.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, UCSI University, No. 1, Jalan Menara Gading, Taman Connaught, Cheras, Kuala Lumpur, 56000, Malaysia.
The third most prevalent type of cancer in the world, colorectal cancer, poses a significant treatment challenge due to the nonspecific distribution, low efficacy, and high systemic toxicity associated with chemotherapy. To overcome these limitations, a targeted drug delivery system with a high cytotoxicity against cancer cells while maintaining a minimal systemic side effects represents a promising therapeutic approach. Therefore, the aim of this study was to develop an efficient gold nanocarrier for the targeted delivery of the anticancer agent everolimus to Caco-2 cells.
View Article and Find Full Text PDFCarcinosarcoma of the fallopian tube: A rare case with rapid metastases and port-site metastasis.
Int J Surg Case Rep
January 2025
Department of Obstetrics and Gynecology, Moriya Daiichi General Hospital, Moriya, Ibaraki, Japan.
Introduction And Importance: Fallopian tube cancer, particularly the carcinosarcoma subtype, is a rare malignancy posing diagnostic challenges.
Case Presentation: Our patient was an 83-year-old, nulligravida woman, presented to our outpatient clinic with one month of pelvic pain. On examination, a pelvic mass was detected.
Optimized Two-Port Laparoscopic-Assisted Ovariohysterectomy for Hydrometra and Pyometra in Small-Sized Dogs.
Animals (Basel)
January 2025
Evergreen Vet Research & Publication, Ichinomiya 491-0914, Japan.
The clinical outcomes of laparoscopic-assisted ovariohysterectomy for the treatment of hydrometra or pyometra in small-sized dogs have not been reported. This study aimed to retrospectively investigate the clinical outcomes of two-port laparoscopic-assisted ovariohysterectomy in small-sized dogs weighing < 6 kg with mild to moderate hydrometra or pyometra. Laparoscopic ports were placed at the umbilicus on the midline, as well as at the midpoint between the umbilicus and pelvic brim.
View Article and Find Full Text PDFDendritic cells connect innate and adaptive immune responses. This is a particularly important immune checkpoint in the case of emerging infections against which most of the population does not have preexisting antibody immunity. In this study, we sought to test whether antibody-based delivery of Ebola virus (EBOV) antigens to dendritic cells could be used as a vaccination strategy against Ebola virus disease.
View Article and Find Full Text PDFTIGIT-expression on natural killer cell subsets is an early indicator of alleviating liver inflammation following bulevirtide treatment in chronic hepatitis D.
Hepatology
January 2025
Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Carl-Neuberg Str. 1, 30625 Hannover, Germany.
Background Aims: Bulevirtide (BLV) is a novel and the only approved treatment option for patients with chronic hepatitis D (CHD). BLV alleviates liver inflammation already early during treatment when only minor HDV RNA changes are observed. We hypothesized that BLV-treatment may influence immune cells in CHD patients and performed a high-resolution analysis of natural killer (NK) cells before and during BLV-therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!